{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:21:14Z","timestamp":1790216474458,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai City Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omto.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T13:56:09Z","timestamp":1647352569000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response"],"prefix":"10.1016","volume":"25","author":[{"given":"Yalei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-9001","authenticated-orcid":false,"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.03.003_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10120-011-0056-y","article-title":"First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer","volume":"15","author":"Iwasa","year":"2012","journal-title":"Gastric cancer"},{"key":"10.1016\/j.omto.2022.03.003_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPA.0000000000000290","article-title":"Pancreatic cancer with malignant ascites: clinical features and outcomes","volume":"44","author":"Takahara","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.omto.2022.03.003_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00280-011-1561-8","article-title":"A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models","volume":"68","author":"Koo","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omto.2022.03.003_bib6","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","article-title":"Evaluation and treatment of malignant ascites secondary to gastric cancer","volume":"21","author":"Maeda","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2022.03.003_bib7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/jjco\/hyq117","article-title":"Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study","volume":"40","author":"Shukuya","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12032-014-0292-1","article-title":"Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial","volume":"32","author":"Zhao","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","article-title":"Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites","volume":"34","author":"Takahara","year":"2016","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.omto.2022.03.003_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2011.11.021","article-title":"A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites","volume":"125","author":"Colombo","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11523-014-0306-0","article-title":"A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion","volume":"9","author":"Mulder","year":"2014","journal-title":"Target Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib13","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00262-007-0310-7","article-title":"Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study","volume":"56","author":"Sebastian","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2022.03.003_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T\u00a0cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omto.2022.03.003_bib17","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.omto.2022.03.003_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. oncolytics"},{"key":"10.1016\/j.omto.2022.03.003_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.gt.3302459","article-title":"Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression","volume":"12","author":"Pipiya","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.03.003_bib21","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3892\/or.2015.4522","article-title":"Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2022.03.003_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omto.2020.06.021","article-title":"Boosting replication and penetration of oncolytic adenovirus by paclitaxel eradicate peritoneal metastasis of gastric cancer","volume":"18","author":"Ishikawa","year":"2020","journal-title":"Mol. Ther. oncolytics"},{"key":"10.1016\/j.omto.2022.03.003_bib23","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.03.003_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omto.2022.03.003_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.omto.2022.03.003_bib26","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","article-title":"Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial","volume":"10","author":"Lu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2022.03.003_bib27","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1016\/j.omto.2022.03.003_bib28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omto.2022.03.003_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/ijo.2015.3045","article-title":"The antitumor effects of oncolytic adenovirus H101 against lung cancer","volume":"47","author":"Lei","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib30","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1002\/jcb.27863","article-title":"The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability","volume":"120","author":"Li","year":"2019","journal-title":"J.\u00a0Cell Biochem."},{"key":"10.1016\/j.omto.2022.03.003_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40880-017-0227-2","article-title":"Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study","volume":"36","author":"He","year":"2017","journal-title":"Chin J. Cancer"},{"key":"10.1016\/j.omto.2022.03.003_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1189\/jlb.1RU0814-382","article-title":"CD4+\/CD8+ double-positive T\u00a0cells: more than just a developmental stage?","volume":"97","author":"Overgaard","year":"2015","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omto.2022.03.003_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bcp.2011.05.019","article-title":"CD3+CD4-CD8- (double negative) T\u00a0cells: saviours or villains of the immune response?","volume":"82","author":"D'Acquisto","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omto.2022.03.003_bib34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: a retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omto.2022.03.003_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of malignant ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.omto.2022.03.003_bib37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fimmu.2018.00335","article-title":"Seroprevalence of neutralizing antibodies against human adenovirus type-5 and chimpanzee adenovirus type-68 in cancer patients","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.omto.2022.03.003_bib38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2019.07.003","article-title":"Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T\u00a0cell metabolism and promote tumor clearance","volume":"51","author":"Rivadeneira","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2022.03.003_bib39","doi-asserted-by":"crossref","first-page":"e85935","DOI":"10.1172\/jci.insight.85935","article-title":"PD-1 marks dysfunctional regulatory T\u00a0cells in malignant gliomas","volume":"1","author":"Lowther","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2022.03.003_bib40","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.4049\/jimmunol.1401936","article-title":"PD-1 upregulated on regulatory T\u00a0cells during chronic virus infection enhances the suppression of CD8+ T\u00a0cell immune response via the interaction with PD-L1 expressed on CD8+ T\u00a0cells","volume":"194","author":"Park","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2022.03.003_bib41","doi-asserted-by":"crossref","first-page":"eaav7431","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.omto.2022.03.003_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-020-02686-6","article-title":"A high number of PD-L1(+) CD14(+) monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors","volume":"70","author":"Ando","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2022.03.003_bib43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.510240314","article-title":"Ultrasonographic determination of ascitic volume","volume":"24","author":"Inadomi","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.omto.2022.03.003_bib44","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jjco\/hym131","article-title":"A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites","volume":"37","author":"Oh","year":"2007","journal-title":"Jpn. J. Clin. Oncol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:21:28Z","timestamp":1762496488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"alternative-id":["S2372770522000456"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.03.003","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}